PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 97.1% from Medutest with 97.9% from the supplier?

Asked 6 Mar 2026Modified 2 months agoViewed 9.5k times
18

What I am working with: 97.1% · Medutest · 97.9%.

I noticed this today and I have not touched anything since, in case the state is diagnostic.

I have not discarded anything yet, so a test is still possible if that is the recommendation.

Is this recoverable, and how would I tell?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
medutest
medutest

Medutest, one of four independent testing and verification services referenced throughout this site. Use this tag for its methods, its report…

126 questions
shareeditfollowflag
HP
askedhana_petrikova10k146 Mar 2026

2 Answers

Accepted answer first, then by votes
59

Accepted answer

0.8 percentage points, and the direction is the informative half. Medutest reports 97.1 per cent and the certificate 97.9, so the independent figure is lower. As impurity that is 2.9 per cent against 2.1 — 1.38 times as much unassigned area. A gentler gradient resolves impurities that a steeper one hides beneath the main peak, so the better method routinely reports the worse number; 0.8 points is comfortably inside what method choice alone produces on identical material. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
CL
answered · acceptedcap_the_luer14k2720 May 2026
7The system-suitability data is the part that tells you whether to believe the rest. – pascal_thibault 8 months ago
8Confirming from the other direction: I ignored the method section once and paid for it. – bac_or_bust 10 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
22

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

In practice, mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
M4
answeredmz_4113101k35831 May 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.